Genomic Grade Index predicts postoperative clinical outcome of GIST

Prognosis of localised gastrointestinal stromal tumour (GIST) is heterogeneous, notably for patients with AFIP intermediate or high risk of relapse, who are candidates to adjuvant imatinib. We hypothesised that gene expression profiles might improve the prognostication and help to refine the indications for imatinib.We collected gene expression and histoclinical data of 146 pre-treatment localised GIST samples treated with surgery alone. We...